From Genome Engineering to Global Recognition: Advancing TIL Therapy Un-TIL It’s Cured

When Drs. Branden Moriarity and Beau Webber helped advance the gene-editing platform behind a recent Lancet Oncology publication, it marked a defining moment for translational cancer science at the University of Minnesota.

The peer-reviewed paper detailed results from a first-in-human clinical trial using CRISPR-edited tumor-infiltrating lymphocytes (TILs) to treat patients with advanced gastrointestinal cancers. By precisely editing a patient’s own immune cells to remove internal brakes that limit their cancer-fighting ability, the team demonstrated both safety and powerful early clinical responses.

One of those patients was Emma Dimery, who had battled late-stage colon cancer for nearly a decade. After receiving a single infusion of her gene-edited TIL cells, her cancer disappeared. She remains in remission today.

The physician-scientist leading this groundbreaking work, Dr. Emil Lou, was recently named to TIME’s 2026 TIME100 Health list, alongside Emma. Their recognition highlights not only a remarkable clinical outcome, but the collaborative ecosystem of clinicians, scientists, engineers, and patients who made it possible.

At the Center for Genome Engineering, Branden and Beau are building and refining the genome editing strategies that allow immune cells to be enhanced with precision. Now, we are launching the next phase of this research through our Un-TIL It’s Cured initiative, designed to expand and strengthen this approach so more patients can benefit. We have raised $1.5 million to initiate this next stage of research thanks to a vast network of community support, local philanthropists, and industry partners.

This work represents more than a scientific milestone. It represents momentum. It represents collaboration. And most importantly, it represents hope.

For patients facing advanced cancers and limited options, gene-edited TIL therapy signals a future where the immune system can be engineered to fight back more effectively than ever before. We will continue advancing this science, expanding access, and pushing forward with urgency and purpose.

Un-TIL it’s Cured.

Learn more about our TIL program and how to support the mission:
https://med.umn.edu/cge/til